GlassScriptPhysician profile
Neil Rubin
NPI 1871583484
$5,041.23
in general payments reported to CMS, 2019-2025
22 companies · $1,518 in 2025
The $1,518 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $247 · 2021: $542 · 2022: $503 · 2023: $746 · 2024: $1,024 · 2025: $1,518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,288.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $762.47 | 2021-2025 | Precision 1, Total30, Tryptyr |
| Bausch & Lomb Americas INC. | $487.89 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Coopervision INC. | $483.87 | 2019-2023 | Myday Contact Lens |
| Glaukos Corporation | $409.72 | 2024-2025 | Photrexa |
| Sight Sciences, INC. | $379.69 | 2019-2023 | Tearcare System |
| Sun Pharmaceutical Industries INC. | $332.23 | 2023-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $280.32 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $247.18 | 2024-2025 | Oxervate |
| Visioneering Technologies, INC. | $219.39 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $214.73 | 2021 | |
| Amgen INC. | $205.80 | 2024-2025 | Tepezza |
| Allergan, INC. | $174.53 | 2021 | |
| Lumenis Be INC | $148.52 | 2022 | |
| Alexion Pharmaceuticals, INC. | $100.07 | 2023 | Soliris |
| Biotissue Holdings INC. | $87.97 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $81.58 | 2025 | Vevye |
| Genzyme Corporation | $77.18 | 2022 | |
| Abbvie INC. | $77.18 | 2022 | |
| Horizon Therapeutics Plc | $77.17 | 2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $73.32 | 2019 | |
| Asd Specialty Healthcare, LLC | $62.16 | 2020 | |
| Maculogix, INC. | $58.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.